Pharma BD Deal Intelligence

Samsung Biologics Co., Ltd. / PolyPeptide Group AG

2026 · Acquisition/Merger · $1.8B · Pending

Samsung Biologics announced an all-cash public tender offer to acquire Swiss peptide CDMO PolyPeptide Group AG at CHF 44.31 per share, valuing PolyPeptide equity at approximately CHF 1.46 billion (about USD 1.8 billion). The transaction marks Samsung Biologics' first move into peptide manufacturing, adding capacity relevant to GLP-1 and other peptide therapeutics and expanding its manufacturing network across the United States, Europe and India. Completion is expected toward the end of 2026, subject to a two-thirds minimum acceptance threshold, regulatory approvals and customary conditions.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals